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Purpose: To report on the phenotype and the genotype of Italian patients carrying BEST1 mutations on both alleles.
Methods: Five Italian patients from four independent pedigrees with retinal dystrophy associated with biallelic BEST1
variants were recruited from different parts of Italy. Molecular genetic analysis of the BEST1 gene was performed with
direct  sequencing  techniques.  All  the  subjects  included  in  the  study  were  clinically  evaluated  with  a  standard
ophthalmologic  examination,  fundus  photography,  optical  coherence  tomography  scan,  and  electrophysiological
investigations. 
Results: Six BEST1 variants were identified. Three, c.1699del (p.Glu557AsnfsX52), c.625delAAC (p.Asn179del), and
c.139C>T (p.Arg47Cys), were novel, and three had already been reported in the literature, c.301C>A(p.Pro101Thr), c.
934G>A (p.Asp312Asn), and c.638A>G (p.Glu213Gly). Four were missense mutations, and two were deletions. Only
one BEST1 mutation was located within one of the four mutational clusters described in typical autosomal dominant Best
vitelliform macular dystrophy (BVMD). Four patients showed a BVMD phenotype while one patient presented a clinical
picture consistent with autosomal recessive bestrophinopathy (ARB). 
Conclusions: Biallelic BEST1 sequence variants can be associated with at least two different phenotypes: BVMD and
ARB. The phenotypic result of the molecular changes probably depends on the characteristics and the combination of the
different BEST1 mutations, but unknown modifying factors such as other genes or the environment may also play a role.
The  human  BEST1  gene  (OMIM  607854;  previously
known as VMD2) is located on the long arm of chromosome
11q12 and consists of 11 exons [1,2]. This gene is expressed
predominantly in the retinal pigment epithelium (RPE) and
encodes  a  585-amino  acid  transmembrane  protein,
bestrophin-1, which localizes to the basolateral membrane of
RPE  cells  [3].  The  BEST1  gene  probably  functions  as  a
chloride channel but has also been considered an inhibitor of
intracellular voltage-dependent Ca2+ channels [4,5].
Mutations  in  the  BEST1  gene  have  been  reported  in
association with different ocular phenotypes [6]. The first
disease shown to be caused by BEST1 sequence variants was
Best vitelliform macular dystrophy (BVMD) [2], a retinal
disease characterized by a bilateral yellowish yolk-like lesion
in the macula [7-9]. BEST1 mutations may also be associated
with  several  other  eye  diseases,  including  adult-onset
vitelliform  macular  dystrophy  (AOVMD)  [10],  autosomal
dominant  vitreo-retinochoroidopathy  (ADVIRC)  [11],
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retinitis pigmentosa [12], and microcornea, retinal dystrophy,
cataract, and posterior staphyloma (MRCS) syndrome [13].
Usually the disorders associated with BEST1 mutations
are inherited as dominant traits. Thus, in typical pedigrees the
affected patients carry a BEST1 mutation on one allele, and
BEST1  mutations  on  both  alleles  are  uncommon.
Nevertheless, isolated patients with a biallelic mutation in
BEST1 and an apparent BVMD phenotype have occasionally
been reported in previous studies on various ethnic groups
[10,14-17].  A  distinct  retinal  disorder,  named  autosomal
recessive  bestrophinopathy  (ARB),  has  recently  been
described in association with biallelic BEST1 mutations [18,
19]. ARB is characterized by RPE dystrophy throughout the
posterior  pole,  associated  with  retinal  edema.  A  BEST1
homozygous change was reported in four patients of the same
family of Pakistani origin; their phenotype was interpreted as
retinitis  pigmentosa  even  though  it  showed  some  clinical
similarities with the ARB phenotype [12]. Recently limited
series  of  patients  with  different  phenotypes  and  carrying
biallelic  BEST1  sequence  variants  have  been  reported
[20-22]. Therefore, the ocular phenotype of patients carrying
a BEST1 mutation on both alleles is still undefined. In the
present paper, we report on the phenotype and the genotype
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3078of five Italian patients from four different pedigrees who carry
BEST1 mutations on both alleles.
METHODS
Clinical evaluation: We first evaluated the medical records of
all  the  patients  whose  blood  samples  were  sent  to  the
Laboratory of the Department of Genetic Diagnosis, Azienda
Ospedaliera Careggi, Florence, Italy, for molecular genetic
analysis of the BEST1 gene. Patients harboring two BEST1
mutations (one for each allele) were invited, together with
their close relatives, for a detailed clinical examination and
for a careful evaluation of their personal and family history.
Five  patients  from  four  independent  pedigrees  were
included in the study (Figure 1). Two were enrolled through
the Hereditary Retinal Degenerations Referring Center of the
Eye  Clinic,  University  of  Florence;  one  was  regularly
followed at the Eye Clinic of the University of Udine, and two
patients  were  recruited  through  the  Genetic  Eye  Disease
Clinic of the Ospedale S.Raffaele, University of Milan, Italy.
Interestingly, the families of both patients from the Florence
unit originated from northeastern Italy.
The study adhered to the tenets of the Declaration of
Helsinki and was approved by the local ethics committees.
Moreover, each patient gave written informed consent for his
or her involvement.
All the subjects included in the study were clinically
evaluated  with  a  standard  ophthalmologic  examination,
fundus photography (Zeiss Retinograph Carl Zeiss, Dublin,
CA, in Florence; TRC 50 IX camera and acquisition software
Imagenet 2000, Topcon Optical Co., Tokyo, Japan, in Udine
and  Milan),  optical  coherence  tomography  (OCT)  scan
(Topcon  3D  OCT-1000,  Topcon  Medical  Systems  Inc.,
Oakland, NJ, in Florence, Stratus Tomographer, model 3000;
Carl Zeiss Meditec, Inc., Humphrey Division, Dublin, CA, in
Udine, and Spectral OCT SLO OPKO/OTI, Miami, FL, in
Milan),  electroculogram  (EOG),  and  electroretinogram
(ERG). Electrophysiological investigations (Retimax, Roland
Consult, Brandenburg, Germany, in Florence; Veris System,
EDI, Inc., San Mateo, CA, in Udine; EREV 2000 LACE
Elettronica, Pisa, Italy in Milan) were performed according to
the existing ISCEV Guidelines [23,24]. Because of the young
age  of  some  of  the  patients,  fluorescein  angiography  and
Figure 1. Pedigrees of the four families included in the study, with segregation of mutations. All affected patients carry biallelic BEST1
mutations.
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3079fundus  autofluorescence  were  performed  only  in  selected
cases.
DNA  extraction  and  PCR  amplification:  After  informed
consent and a complete family history were received, 10 ml
of peripheral blood were obtained from the antecubital vein
using  EDTA-containing  vials.  DNA  was  extracted  from
200 μl peripheral using an automated method involving the
BioRobot EZ1 workstation (QIAGEN GmbH, Germany).
PCR  amplification  of  11  exons  and  flanking  intronic
regions of the BEST1 gene was performed using 50–100 ng
of genomic DNA. Amplification was performed in 50 mmol/
l  KCl,  10  mmol  /l  Tris-HCl,  pH  8.3,  5  mmol/l  MgCl2,
200  μmol/l  dNTPs,  and  0.5  μmol/l;  for  each  primer  set,
AmpliTAq DNA polymerase (1 Unit of Ampli TAq Gold;
Applied Biosystems, Foster City, KA) was added for each
25 μl reaction. PCR was performed with a multiblock MWG
PCR  System;  cycling  parameters  for  the  reactions  were
optimized for each exon: 95 °C for 13 min and then 30 cycles
of 95 °C for 1 min; “x” °C for 1 min; 72 °C for 51 min (for
which x °C is the primers’ annealing temperature) with a final
extension of 72 °C for 10 min. The primers used are shown in
Table 1. PCR amplification was performed using the Core
System-Robotic Station (Beckman Coulter). PCR products
were purified with a Biomek NX station (Beckman Coulter).
Mutational  analysis:  Standard  cycle-sequencing  reactions
with  BigDye  Terminator  Mix  v1.1  (Applied  Biosystems)
contained 3–10 ng of purified PCR products in 20 μl and were
performed with forward and reverse primers for the initial
amplification. The sequencing reactions were precipitated,
dried,  and  then  sequenced  on  a  sequencer  3730  DNA
Analyzer. Finally, data obtained from the Sequence Analysis
Software (Applied Biosystems) were aligned with the wild-
type BEST1 gene sequence (GenBank Database). According
to the EMQN Best Practice Guidelines, a sequence mismatch
was considered a disease-causing mutation only if absent in
300 healthy controls, associated with amino acidic change,
and confirmed with a new independent PCR.
Alamut 1.5 software (Interactive Biosoftware, Rouen,
France) was used to interpret the unclassified variants.
RESULTS
Family A: A 6-year-old child (patient A-3) with a history of
macular dystrophy and reduced vision was referred to the Eye
Clinic  of  the  University  of  Florence  in  May  2006.  On
examination, the best corrected visual acuity (BCVA) was
20/32  right  eye  (OD)  and  20/50  left  eye  (OS).  Fundus
examinations revealed a vitelliform disc in the vitelliruptive
stage in the macular area in both eyes (OU). In OS, two
extrafoveal additional vitelliform discs were detected in the
temporal area at the posterior pole. EOG showed an Arden
ratio  of  1.00  OD  and  1.12  OS.  The  photopic
electroretinographic  (ERG)  response  was  within  normal
limits while scotopic ERG showed a reduced amplitude (about
25% compared with the average values of the control group).
In  January  2008,  the  young  patient  developed  choroidal
neovascularization (CNV) with macular hemorrhage in OS
and received two photodynamic therapy (PDT) treatments.
At the last examination in July 2010, BCVA was 20/50
OD and 20/100 OS. In OD, fluorescein angiography showed
a round hypofluorescent area due to the vitelliform disc, with
irregular areas of hyperfluorescence related to localized RPE
atrophy,  without  dye  leakage;  in  OS,  hyperfluorescent
abnormalities were detected in the macular area, in association
with staining of the fibrotic areas, without any sign of dye
leakage (Figure 2). OCT scans passing through the macula
showed in OU an optically empty lesion with clumping of
hyperreflective material on the posterior retinal surface and
some irregular thickening of the RPE layer (Figure 2). The
patient’s father (patient A-1, age 43 years), mother (patient
A-2, age 43 years), and younger brother (patient A-4, age 10
years)  showed  normal  visual  acuity,  normal  fundus
appearance, and normal ERG. The EOG response was normal
for the proband’s parents (the Arden ratio was 2.40 OD and
3.61 OS for the father, and 1.88 OD and 2.31 OS for the
TABLE 1. PRIMERS USED FOR THE PCR AMPLIFICATION OF THE BEST1 GENE.
Exon Sense primer (5′-3′) Antisense primer (5′-3′) Annealing
temperature (°C)
1 ACCCAACACCCTCCAAGAA AGTCCACCTGGGGCACCTT 60
2 CCCTACAAACCCCCAATCG CCAGCCACATCCTTCCCAG 60
3 AGTCTCAGCCATCTCCTCGC TGGCCTGTCTGGAGCCTG 60
4 AGAAAGCTGGAGGAGCCGA TTCACCCATCTTCCATTCCT 58
5 GCCATCCCTTCTGCAGGTT GCGGCAGCCCTGTCTGTAC 62
6 GGGGCAGGTGGTGTTCAGA GGCAGCCTCACCAGCCTAG 60
7 TGATTTCAGGGTTCCCACCTAG CATCCTCGTCTCAGGCAGCT 65
8 AGGGTTTACAGAGCCTCACCTG CACTTTGGGGAAGGTCCATG 60
9 CCTCCAAGTCATCAGGCACATA CTAGGCAGACCCCTGCACTAG 65
40817 ACTGGCTCAGCCCTGCATC GTGGGGCACTGTAGTAGCCTG 60
40818 CCTTCAAGTCTGCCCCACTG TGCAGTGCCCCTGGTTC 60
11 GGTACCTTCCATACTTATGCTG AGGTCTTGGGATGAATCAGA 60
               For each exon the forward primer, the reverse primer, and the annealing temperature are indicated.
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3080mother), while the brother showed a reduced Arden ratio (1.23
OD and 1.11 OS).
In the proband, molecular analysis detected two sequence
variants  of  the  BEST1  gene  in  the  heterozygous  state:  c.
Figure 2. Fundus photographs, fluorescein angiography, and optical coherence tomography (OCT) scans of patient A-3. A, B: Bilateral
vitelliform disc in the vitelliruptive stage resulting in (C, D) a macular hypofluorescent lesion with irregular areas of hyperfluorescence and
(B) smaller multifocal vitelliform discs resulting in (D) hypofluorescent areas in left eye (OS). E, F: Bilateral macular optically empty lesions
with clumping of hyperreflective material on the posterior retinal surface and some irregular thickening of the RPE layer. OD represents the
right eye.
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3081934G>A (p.Asp312Asn) already described in the literature in
association  with  BVMD  and  the  novel  variant  c.1699del
(p.Glu557AsnfsX52) [10]. Both mutations were absent in 300
healthy controls of Italian origin. The second variant is a single
base pair deletion and gives rise to a premature stop after 52
nucleotides;  therefore,  a  pathogenic  effect  is  likely.  The
variant could not be evaluated with the Alamut software,
which  provides  a  predictive  evaluation  only  for  missense
mutations. The patient’s father carried the mutation c.1699del
(p.Glu557AsnfsX52) in the heterozygous state and the mother
and the brother the mutation c.934G>A (p.Asp312Asn) in the
heterozygous  state.  The  pedigree  of  the  family  and  the
segregation of the mutations are shown in Figure 1.
Family B: In 2006 patient B-3 was referred to the Eye Clinic
of  the  University  of  Udine  at  the  age  of  6  because  she
complained of mild visual impairment. BCVA was 20/20 OD
and 20/25 OS. Fundus appearance was normal in OD while
OS showed a vitelliform disc at the posterior pole (Figure 3).
EOG was abnormal in OU, with an Arden ratio of 1.07 OD
and 0.89 OS. The amplitude of the ERG response was slightly
reduced for all the components (about 30% compared with the
average values of the control group). OCT scans showed a
normal  macular  profile  in  OD  and  an  accumulation  of
hyperreflective material between the RPE and the neuroretina
in OS (Figure 3). The clinical picture remained stable until the
last examination in May 2010.
The patient’s father (B-1, age 38 years) and mother (B-2,
age 37 years) had normal visual acuity and normal fundus
appearance, and their ERG and EOG responses were within
normal limits (1.75 OD and 1.80 OS for the father and 1.78
OU for the mother). Molecular analysis detected in this patient
a  novel  BEST1  gene  sequence  variant,  c.625delAAC
(p.Asn179del),  in  the  homozygous  state.  This  mutation
consists of an in-frame deletion of three base pairs and does
not give rise to a premature stop. The mutation was absent in
300 healthy controls of Italian origin. The same mutation was
detected in both parents in the heterozygous state (Figure 1).
The mutation could not be processed by the Alamut software
Figure 3. Fundus photographs and optical coherence tomography (OCT) scans of patient B-3. A: Normal fundus in right eye (OD) and (B)
vitelliform disc in the vitelliruptive stage in left eye (OS). C: Normal macular profile in OD and (D) central RPE detachment with
hyperreflective material in OS.
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3082because  its  scoring  systems  do  not  provide  a  predictive
evaluation for deletions.
Family C: The proband (patient C-3) was referred to the Eye
Clinic of the University of Milan in 2004 at age 15 with a
history of reduced vision in both eyes. At examination, BCVA
was 20/40 OU. Fundoscopy showed at the posterior pole a
vitelliform disc in the vitelliruptive stage with contiguous
RPE dystrophy below the macula in OU (Figure 4). An OCT
scan  showed  a  bilateral  macular  optically  empty  zone
containing  partially  reabsorbed  hyperreflective  material
(Figure 4). ERG was within normal limits while EOG was
abnormal with an Arden test of 1.20 OD and 1.54 OS. The
clinical  picture  remained  unchanged  at  the  following
ophthalmologic examinations in 2008 and 2010. The patient
was the product of a consanguineous marriage. The parents
underwent an ophthalmological examination in 2008, when
the father (C-1) was 50 years old and the mother (C-2) was 47
years old; they had normal visual acuity and normal fundus
appearance but were not available for electrophysiological
testing. Molecular analysis detected in this patient a novel
BEST1 gene sequence variant, c.139C>T (p.Arg47Cys), in
the homozygous state. The same mutation was detected in
both parents in the heterozygous state. The mutation was
absent in 300 healthy controls of Italian origin. This novel
mutation was located in a weakly conserved region of the
protein, even though it was associated with a substitution
involving two aminoacids with different chemical properties;
the Alamut software classified the mutation as a tolerated
change that may possibly affect the protein function, with a
potentially low pathogenic effect.
The fourth patient (C-4) was the younger sister of the
previous patient. She complained of bilateral visual reduction
in 2008 at age 13. At examination, BCVA was 20/32 in both
eyes. Fundus examination showed a bilateral vitelliform disc
in the macular area (Figure 5). ERG was within normal limits,
while the EOG showed an Arden test value of 1.65 OU. OCT
scans showed a bilateral hyperreflective dome-shaped lesion
located between the RPE and the neuroretina (Figure 5). The
clinical picture was stable until the last examination in April
2010. The patient carried in the homozygous state the same
BEST1 sequence variant c.139C>T (p.Arg47Cys) found in the
parents in the heterozygous state and in her elder brother in
the homozygous state (Figure 1).
Family D: In January 2010, a 16-year-old girl (patient D-3)
from northern Italy was referred to the Eye Clinic of the
University of Florence with a history of reduced vision in both
eyes  that  started  when  she  was  about  6  years  old.  At
examination,  her  BCVA  was  20/25  OD  and  20/50  OS.
Fundoscopy  showed  in  OU  diffused  RPE  dystrophy  with
yellowish deposits at the posterior pole and macular edema
(Figure 6). The medical records of the patient demonstrated
that no vitelliform disc had ever been detected during the
course of the disease. An OCT scan showed bilateral macular
Figure 4. Fundus photographs and optical coherence tomography (OCT) scans of patient C-3. A, B: Bilateral vitelliform discs in the
vitelliruptive stage with retinal pigment epithelium (RPE) dystrophy inferiorly to the macula. C, D: Macular optically empty lesions containing
partially reabsorbed hyperreflective material. OD represents the right eye; OS represents the left eye.
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3083cystoid  spaces  (Figure  6).  Scotopic  ERG  was  abnormal
(amplitude was reduced by about 50% of the average value of
the control group) while photopic ERG amplitude was slightly
reduced (about 25% of the average values of the controls). The
EOG  Arden  test  values  were  1.20  OD  and  1.50  OS.
Fluorescein angiography showed macular hyperfluorescence
and small hyperfluorescent spots at mid-periphery, with a
higher concentration around the optic disc (Figure 6). In 2008,
the patient had received PDT for suspected CNV in OD.
The patient’s father (D-1, age 48 years) and mother (D-2,
age 47 years) showed normal visual acuity, normal fundus
appearance, and ERG response within normal limits. The
mother’s EOG response was normal (the Arden ratios were
1.83 OD and 1.72 OS) while the father presented an Arden
ratio of 1.35 OU. The patient’s younger brother (D-4) was
examined in another hospital in 2004 when he was 5 years old;
at that time, visual acuity and fundus appearance were normal.
He was not available for further investigations.
In the proband, molecular analysis detected two sequence
variants  of  the  BEST1  gene  in  the  heterozygous  state:  c.
301C>A (p.Pro101Thr) and c.638A>G (p.Glu213Gly); both
have already been described in the literature in association
with BVMD [25,26]. They were absent in 300 healthy controls
of Italian origin. The patient’s father carried the mutation c.
301C>A  (p.Pro101Thr)  in  the  heterozygous  state  and  the
mother  the  mutation  c.638A>G(p.Glu213Gly)  in  the
heterozygous state (Figure 1).
DISCUSSION
BEST1 mutations are usually associated with dominant retinal
disorders,  and  therefore  homozygous  or  compound
heterozygous mutations are rare [6]. We report on a series of
Italian patients carrying mutations of the BEST1 gene on both
alleles.
Two of our patients were compound heterozygotes while
three patients (two from the same family) were homozygotes.
A  significant  clinical  difference  between  the  compound
heterozygous and homozygous patients could not be detected
in  our  series;  compound  heterozygous  mutations  were
associated with a case of unilateral BVMD and with an ARB
phenotype.
We identified six BEST1 variants. Three were novel, and
three have already been reported in the literature in association
with BVMD, c.301C>A (p.Pro101Thr) [25] and c.638A>G
(p.Glu213Gly) [26], or AOVMD, c.934G>A (p.Asp312Asn)
[10]. Four were missense mutations, and two were deletions.
Only one mutation, c.301C>A (p.Pro101Thr), was located
within one of the four mutational clusters described in typical
autosomal  dominant  BVMD  [6].  Two  of  the  detected
mutations,  c.934G>A  (p.Asp312Asn)  and  c.139C>T
(p.Arg47Cys), have already been reported in patients carrying
another  BEST1  mutation  on  the  other  allele  [18,22].
Interestingly,  the  patient  with  c.934G>A  (p.Asp312Asn)
showed  an  ARB  phenotype  [18]  while  the  c.139C>T
(p.Arg47Cys)  mutation  (in  the  homozygous  state)  was
Figure 5. Fundus photographs and optical coherence tomography (OCT) scans of patient C-4. A, B: Bilateral vitelliform discs in the
vitelliruptive stage. C, D: Bilateral hyperreflective dome-shaped lesions located between the RPE and the neuroretina. OD represents the right
eye; OS represents the left eye.
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the posterior pole, a clinical picture more similar to classical
BVMD [22]. Moreover, in our series two of the six mutations
are located between aminoacids Arg 141 and Lys 289 of the
Figure 6. Fundus photographs, fluorescein angiography, and optical coherence tomography (OCT) scans of patient D-3. A, B: Widespread
RPE dystrophy and yellowish deposits at the posterior pole with (C, D) bilateral macular hyperfluorescence and small hyperfluorescent spots
at the posterior pole and mid-periphery. E, F: Bilateral macular cystoid spaces and two cleavage plans: the outer one between the retinal
pigment epithelium (RPE) and the neuroretina and the inner one below the nerve fibers layer. OD represents the right eye; OS represents the
left eye.
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3085bestrophin  protein  where  a  higher  frequency  of  BEST1
biallelic mutations have recently been reported [22].
The relatively high rate of novel mutations, the report of
frequent  deletions  (rarely  associated  with  the  BVMD
phenotype),  the  predominant  location  outside  the  BVMD
mutational clusters, and the recurrence of some variants in the
recessive  form  of  the  disease  may  suggest  that  certain
mutations have a higher predisposition to be pathogenic when
present on both alleles.
In  our  series,  the  biallelic  BEST1  mutations  are
associated with two different phenotypes, BVMD and ARB.
This  agrees  with  recent  reports  of  the  association  of
homozygous or compound heterozygous BEST1 variants with
different clinical pictures, ranging from the classical form of
BVMD [20,22] to ARB [18,19,22], including some atypical
phenotypes [21,22].
The clinical picture of patients A-3, B-3, C-3, and C-4
was consistent with BVMD, although with mild phenotypic
differences. The patients had abnormal EOG while ERG was
slightly abnormal in patients A-3 and B-3 and normal in the
remaining patients. The relatives of patients A-3, B-3, C-3,
and  C-4  presented  normal  visual  acuity,  normal  fundus
appearance, and ERG response within normal limits. EOG
was within normal limits for the parents of the patients A-3
and B-3 but showed a reduced Arden ratio for patient A-4, the
younger brother of the proband A-3.
Isolated cases of patients with biallelic BEST1 mutations
and  a  BVMD  phenotype  have  already  been  reported  in
literature [10,14-17].
In  most  of  the  cases,  clinical  and  histopathological
abnormalities  were  comparable  to  those  found  in
heterozygous patients [15]. Similarly, our BVMD patients did
not show a significantly more severe picture than that usually
described  in  BVMD  patients  carrying  a  single  BEST1
mutation; nevertheless, mild ERG abnormalities were found
in patients A-3 and B-3. The clinical expressivity was variable
as the BEST1 biallelic variants were associated with typical
but also multifocal or unilateral BVMD phenotypes.
The heterozygous relatives of our BVMD patients did not
have fundus or ERG abnormalities and showed normal EOG
responses in most of the cases. Clinical data on heterozygous
relatives of patients carrying BEST1 biallelic mutations have
not  been  reported  in  detail  in  the  literature;  we  can  only
speculate  from  the  available  data  that  some  heterozygous
relatives may be clinically affected while others may show a
normal fundus appearance [10,15-17]. In a recent paper, the
heterozygous  relatives  of  a  patient  with  a  homozygous
BEST1 mutation associated with a classical BVMD phenotype
showed neither fundus nor EOG abnormalities [20].
The phenotype of patient D-3 was significantly different
from those of the other patients, and it is consistent with the
clinical diagnosis of autosomal recessive bestrophinopathy
(ARB) [18,19].
This  patient  carried  two  BEST1  mutations  already
described  in  the  literature  in  association  with  BVMD.
BEST1  variants  detected  in  association  with  the  ARB
phenotype have already been reported in BVMD [10,14] and
in  AOVMD  [22].  These  data  are  consistent  with  the
hypothesis that in patients carrying biallelic BEST1 mutations
the resulting phenotype is determined by the interaction of the
pathogenic effects of the different mutations on both alleles.
The abnormal EOG response of the patient’s father is not
in agreement with previous reports where all the heterozygous
carriers  showed  a  normal  EOG  [18].  EOG  abnormalities
reported in isolated heterozygous cases of clinically healthy
relatives of patients carrying biallelic BEST1 mutations may
be  related  to  the  influence  of  unknown  genetic  or
environmental factors, even if technical problems or poor
collaboration from the patient cannot be excluded.
Previous  findings  and  our  observations  show  that
sequence variants of the BEST1 gene on both alleles can be
associated with at least two different phenotypes, BVMD and
ARB.  The  phenotypic  result  of  the  molecular  changes
probably depends on the characteristics and the combination
of  the  different  BEST1  sequence  variants,  but  unknown
modifying factors such as other genes or the environment may
also play a role.
Because  of  this  phenotypic  heterogeneity,  BEST1
mutations may be involved in retinal diseases other than those
already  identified.  A  clearer  understanding  of  the  BEST1
mutations  spectrum  and  its  associated  phenotypes  is
warranted for better clinical evaluation, genetic counseling,
and patient selection for possible future treatments.
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